asp3291
Peptideexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Aug 1, 2010 (NCT01320332)
Timeline
Indications
Studied for
Mechanism of action
- Melanocortin receptor 1AGONIST
MC1R agonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- asp3291
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01612039 | Phase 2 | Jul 1, 2012 | Drais Pharmaceuticals, Inc., Telsar Pharma Inc. |
| NCT01320332 | Phase 1 | Aug 1, 2010 | Astellas, Telsar Pharma Inc. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Telsar Pharma Inc. | For profit | 2 | 2 | 2 | 2010 |
| Astellas | For profit | 1 | 0 | 1 | 2010 |
| Drais Pharmaceuticals, Inc. | For profit | 1 | 0 | 1 | 2012 |
3 organizations
Page 1 / 1